Claude autonomously designs protein binders that work in the lab against 14 of 15 targets
Result confirmed
Importance: major (4 of 5)The takeaway
On Aug 18, 2026 Anthropic reported that Claude (Mythos Preview and Opus 4.8), running autonomously in Claude Science, designed de novo protein binders against 15 targets and produced confirmed binders for 14 of them in outside wet-lab tests by Adaptyv Bio and Twist Bioscience.
Status
- Claim
Result confirmed
- Our reporting
- High confidence
- Verification
- Expert-checked
- Importance
- Major (4 of 5)
- Last verified
- 7 October 2026
Your AI and this story
- GPT-6.2 Astra79 days after its cutoff
- Claude Opus 5.549 days after its cutoff
- Gemini 4 Hydrogen140 days after its cutoff
- Grok 4.779 days after its cutoff
None of these four assistants can know about it. The closest, Claude Opus 5.5, stops 49 days before it.
Key facts
- 354 confirmed binders from 1,320 designs, against 14 of 15 targets (30 designs requested per target)
- Hit rates: Mythos Preview 26.7% and Opus 4.8 22.6% in multi-target mode (48 h, up to 12,500 H100 hours); Mythos Preview 35.1% in single-target mode (24 h, up to 2,500 H100 hours per target). Anthropic cites 10–15% as typical
- Wet-lab production and testing done independently by Adaptyv Bio and Twist Bioscience
- High-affinity binders against at least six targets; binders matching or exceeding the best reported affinity against at least four
- RBX1: Mythos Preview reached a 40% hit rate vs 3.7% among Adaptyv competition participants; its top design outperformed the winning entry (245 designs entered)
- Opus 4.8, not Mythos Preview, succeeded on the hard target TNFα, including binders cross-reactive to human, cynomolgus monkey and mouse TNFα
- Failures: no confirmed binder against maltose-binding protein (0 of 90 designs); only three modest binders against the de novo β-barrel BBF-14
- Humans only granted access approvals and monitored infrastructure after the initial prompt; prompts and all in vitro and in silico data released
Show 2 more
- Chemistry test: Opus 5 in Claude Science returned processed NMR and LC-MS results in 23 and 19 minutes from raw vendor files; purity 96.4% vs the lab’s 96.33%. It decoded an undocumented LC-MS format, checked against all 2,664 scans
- Protein design and other dual-use biology stay blocked in generally available Claude Fable 5; Anthropic said an access program for scientists was a top priority
What happened
Anthropic ran a multi-arm binder design campaign in Claude Science. Claude chose binding sites on each target, orchestrated open-source structure-design, sequence-design and co-folding models, ran several rounds of in silico optimization and screened candidates. After the first prompt nobody gave it scientific guidance. Adaptyv Bio and Twist Bioscience then made and tested the designs. Anthropic described the 354 binders as a sizeable addition to public de novo binder data. By comparison, it counted about 770 binders from 5,700 designs across 40 targets in the two largest existing public collections.
The post also tested a generally available model, Opus 5, on routine analytical chemistry. Working only from a contract lab’s raw instrument files, it reproduced the lab’s NMR and purity results. It also proposed the same heavy-water follow-up test that the lab had run on its own.
Why it matters
It was among the first wet-lab-validated demonstrations of a general-purpose LLM agent running a whole protein design campaign at or above expert level. It was the basis for Anthropic’s later work to make the pipeline cheaper (Sept 17) and for its Life Sciences Verification Program. The results are the company’s own, and the hit-rate comparisons use Anthropic’s baseline figures. Anthropic says it will characterize the binders further to confirm hit rates and affinities.
Sources
4 sources from 4 sites. Numbers match the chips in the text.
4 sources: 1 primary, 3 press
Primary
- Anthropic: How Claude is accelerating protein design and analytical chemistryanthropic.com, official
Press
- The Next Web: Anthropic says Claude designed working protein binders, and beat human experts on somethenextweb.com, press
- Dataconomy: Claude designed protein binders for 14 of 15 targetsdataconomy.com, press
- pharmaphorum: Claude Science outperforms experts in protein binder taskpharmaphorum.com, press
Changes
- Science block: kind: other (not a long-open problem; listed with other AI science results, not in the open-problems count)
- Filed (the post had not been cited)